News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|October 19, 2021

Patient Case #2 Continued: Novel Second-Generation Antipsychotics

Author(s)Michael E. Thase, MD, Gustavo Alva, MD, DFAPA, Theresa Cerulli, MD

A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.

Episodes in this series

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 1 Patient Case #1: 27-Year-Old Woman With Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 2 Clinical Significance of Bipolar Disorder

EP. 3 Clinical Impressions From Patient Case #1

EP. 3 Clinical Impressions From Patient Case #1

EP. 4 Diagnosis of Bipolar Disorder

EP. 4 Diagnosis of Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 5 Treatment Options for Bipolar Disorder

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 6 Patient Case #2: 47-Year-Old Man With Treatment Resistant Depression (TRD)

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 7 Patient Case #2 Continued: Novel Second-Generation Antipsychotics

EP. 8 Role of Telemedicine in Bipolar Disorder

EP. 8 Role of Telemedicine in Bipolar Disorder

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

categories

Categories vs Dimensions: Wave or Particle?

ByS. Nassir Ghaemi, MD, MPH,Mark L. Ruffalo, MSW, DPsa

July 29th 2026

bipolar woman

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy

ByAshley A. Mulvihill, MD ,Susan Hatters Friedman, MD, MSt, DFAPA

July 17th 2026

nibelheim/Adobe Stock

Brain Trust: Addiction Pharmacotherapy in Bipolar Disorder, Rethinking Comorbidity With Michael J. Ostacher, MD, MPH

ByJoseph F. Goldberg, MD,Michael J. Ostacher, MD, MPH

July 1st 2026

bipolar

Podcast: Practical Insights Into the Evolving Treatment of Bipolar Disorder With David Dunner, MD, FACPsych

ByJoseph F. Goldberg, MD,David Dunner, MD, FACPsych

June 26th 2026

Keeping Up To Date With Bipolar Disorder

ByMichael E. Henry, MD

June 15th 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

A New Mechanism for ADHD: Raman Baweja, MD, on Centanafadine's FDA Approval

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

A Preventive Window In Post-TBI Care and Subsequent Alzheimer Pathology

From Fibromyalgia to Depression: TNX-102 Sublingual Cyclobenzaprine Trials for MDD